Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
Titel:
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
Auteur:
Foley, John F Defer, Gilles Ryerson, Lana Zhovtis Cohen, Jeffrey A Arnold, Douglas L Butzkueven, Helmut Cutter, Gary Giovannoni, Gavin Killestein, Joep Wiendl, Heinz Smirnakis, Karen Xiao, Shan Kong, George Kuhelj, Robert Campbell, Nolan